Durable responses in chronic myeloid leukemia patients maintained with lower doses of imatinib mesylate after achieving molecular remission

By Carella Angelo   Lerma Enrica  

Annals of Hematology, Vol. 86, Iss. 10, 2007-10 ,pp. : 749-752

Springer Publishing Company

Access to resources Recommend Favorite

Effect of LMO2 protein expression on survival in chronic myeloid leukemia patients treated with imatinib mesylate

By Sonmez Mehmet   Akagun Tulin   Cobanoglu Umit   Topbas Murat   Erkut Nergiz   Yilmaz Mustafa   Ovali Ercument   Omay Serdar Bedii  

Hematology, Vol. 14, Iss. 4, 2009-08 ,pp. : 220-223

Maney Publishing

Access to resources Recommend Favorite

Aberrant DNA Methylation of SOCS1 Gene is Not Associated with Resistance to Imatinib Mesylate among Chronic Myeloid Leukemia Patients

By  

Cardiovascular & Haematological Disorders - Drug Targets(Formerly Current Drug Targets - Cardiovascular & Hematological Disorders), Vol. 18, Iss. 3, 2018-12 ,pp. : 234-238

Bentham Science Publishers

Access to resources Recommend Favorite

Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase

By Giles F.J.   Feldman E.J.   Roboz G.J.   Larson R.A.   Mamus S.W.   Cortes J.E.   Verstovsek S.   Faderl S.   Talpaz M.   Beran M.   Albitar M.   O'Brien S.M.   Kantarjian H.M.  

Leukemia Research, Vol. 27, Iss. 12, 2003-12 ,pp. : 1091-1096

Elsevier

Access to resources Recommend Favorite

Molecular evidence for antigen-driven immune responses in cardiac lesions of rheumatic heart disease patients

By Charron D.  

International Immunology, Vol. 12, Iss. 7, 2000-07 ,pp. : 1063-1074

Oxford University Press

Access to resources Recommend Favorite